GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Calliditas Therapeutics
Calliditas is a Swedish biopharmaceutical company focused on treating rare kidney diseases. Its share price is dependent on sales of its approved drug Tarpeyo and its success in expanding its use.
Share prices of companies in the market segment - Pharma kidney
Calliditas Therapeutics is a Swedish biopharmaceutical company specializing in developing treatments for rare kidney diseases. We've categorized it under "Pharma: Kidney," and the chart below shows how investors value companies in this highly specialized field.
Broad Market Index - GURU.Markets
Calliditas Therapeutics is a Swedish biopharmaceutical company specializing in developing treatments for rare kidney diseases. Its focus on this niche makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Calliditas compares to it.
Change in the price of a company, segment, and market as a whole per day
CALT - Daily change in the company's share price Calliditas Therapeutics
For Calliditas Therapeutics AB, which develops drugs to treat kidney diseases, daily volatility reflects its sensitivity to drug sales. This metric is an important element of analysis in this niche.
Daily change in the price of a set of shares in a market segment - Pharma kidney
Calliditas Therapeutics is a Swedish biopharmaceutical company specializing in the treatment of rare kidney diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing CALT stock performance.
Daily change in the price of a broad market stock, index - GURU.Markets
Calliditas is a Swedish biopharmaceutical company specializing in kidney disease treatment. Its US-listed shares bring the dynamism of the European biotech sector to the market. These international factors complicate the overall market volatility picture.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Calliditas Therapeutics
Calliditas Therapeutics' year-over-year performance is a story of the commercialization of its drug for a rare kidney disease. Its market capitalization growth over the past 12 months reflects its successful sales of Tarpeyo®, the first approved drug for IgA nephropathy, a fundamental milestone that transformed the company into a commercial company.
Annual dynamics of market capitalization of the market segment - Pharma kidney
Calliditas Therapeutics is a commercial-stage biopharmaceutical company focused on treating rare kidney diseases. Its success depends on the commercialization of its approved drug. The chart shows how its niche strategy and competitive environment influence its performance in the pharmaceutical sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Calliditas, with the approval of its kidney drug, has entered a new league. Its current performance relative to the market is a test of its sales ability. Outperforming the market will indicate a successful launch and revenue growth, while lagging behind will indicate difficulties with market entry.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Calliditas Therapeutics
Calliditas is a commercial biopharmaceutical company. Its monthly performance is now dependent on the commercial success of its kidney disease drug Tarpeyo. Sales data and geographic expansion are becoming key drivers.
Monthly dynamics of market capitalization of the market segment - Pharma kidney
Calliditas Therapeutics is a Swedish biopharmaceutical company that developed the first drug approved for the treatment of a rare kidney disease (IgA nephropathy). The chart below shows how investors assessed the commercial potential of orphan disease drugs and the prospects of companies operating in this complex niche.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Calliditas Therapeutics is a Swedish pharmaceutical company specializing in the treatment of kidney diseases. Its stock price is driven by the commercial success of its drug in the US and Europe, as well as the results of further studies. It is a focused international pharmaceutical company.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Calliditas Therapeutics
Calliditas Therapeutics is a Swedish biopharmaceutical company whose lead drug is designed to treat a rare kidney disease. Its weekly stock price is driven by sales reports for this drug in the US and Europe and news of its approval in other countries.
Weekly dynamics of market capitalization of the market segment - Pharma kidney
Calliditas Therapeutics focuses on treating kidney diseases. Like many niche pharmaceutical companies, its shares react strongly to clinical trial data and regulatory decisions. The chart will reveal whether Calliditas's performance is driven by its unique progress or reflects a general investor reaction to developments in the nephrology sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Calliditas is a Swedish pharmaceutical company. Its shares (ADRs) follow the rhythm of news about clinical trials and drug approvals. The chart clearly shows how much its performance is detached from the stock market and is determined by its own scientific successes or failures.
Market capitalization of the company, segment and market as a whole
CALT - Market capitalization of the company Calliditas Therapeutics
Calliditas Therapeutics' market capitalization chart essentially reflects the market valuation of its leading drug for the treatment of a rare kidney disease (IgA nephropathy). The robust growth on the chart reflects the successful approval and commercialization of this drug. Investors are betting that it will become a standard treatment and achieve market dominance.
CALT - Share of the company's market capitalization Calliditas Therapeutics within the market segment - Pharma kidney
Calliditas Therapeutics is a biotech company focused on rare kidney diseases. Its market share in the pharmaceutical sector is small but significant within its niche. This metric reflects the market's appreciation of its lead drug and its potential to treat specific diseases where competition is limited.
Market capitalization of the market segment - Pharma kidney
The graph below shows the trillion-dollar value of the pharmaceutical sector. Calliditas Therapeutics is an example of a successful niche strategy. The company focused on a rare kidney disease and brought an approved drug to market. Its success in a gigantic market is a classic biotech story, proving that focusing on a specific problem can lead to great success.
Market capitalization of all companies included in a broad market index - GURU.Markets
Calliditas is a Swedish pharmaceutical company that developed the first drug to treat the rare kidney disease IgA nephropathy. Its market capitalization is based on the success of this product. The chart below shows the economic weight a company can wield by solving a single, yet important, problem.
Book value capitalization of the company, segment and market as a whole
CALT - Book value capitalization of the company Calliditas Therapeutics
Calliditas's book value is derived from its intellectual property rights to the nephropathy drug TARPEYO/KINPEYGO and the capital available for its commercialization and further research. The graph tells the story of a biotech company's transformation from development to commercialization, where the success of a single product begins to build a solid financial foundation.
CALT - Share of the company's book capitalization Calliditas Therapeutics within the market segment - Pharma kidney
Calliditas Therapeutics is a pharmaceutical company whose value is created in laboratories. The chart shows its share of actual R&D assets. These are its research centers where drugs for rare kidney diseases are developed and tested.
Market segment balance sheet capitalization - Pharma kidney
Calliditas Therapeutics is a pharmaceutical company specializing in the treatment of kidney diseases. Their value lies in their patents and clinical trial results, not their manufacturing plants. A book value chart will show their R&D base, but it won't reflect the potential value of their intellectual property.
Book value of all companies included in the broad market index - GURU.Markets
Calliditas's resources include laboratories and R&D centers where innovative therapies for kidney diseases were developed. The chart shows how the company built its scientific and physical capital to bring its lead drug to market.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Calliditas Therapeutics
The Calliditas chart is an indicator of faith in the success of its key kidney drug. The company's book value is derived from its laboratories and financials. Its market value, however, reflects the hope for future billion-dollar sales of the drug. Every jump in the chart is a reaction to positive clinical trial news, detaching the valuation from its tangible assets.
Market to book capitalization ratio in a market segment - Pharma kidney
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on treating rare kidney diseases. Its valuation depends almost entirely on the commercial success of its key drug. The chart shows how its market capitalization, based on expected future sales and patents, compares to its current tangible assets.
Market to book capitalization ratio for the market as a whole
Calliditas Therapeutics is a biotech company whose value is determined by its pipeline and patents. This chart demonstrates that the market values the potential of future drugs, not current assets. A huge premium to market capitalization over book value is typical for successful pharmaceutical companies, where a single successful development can generate billions.
Debts of the company, segment and market as a whole
CALT - Company debts Calliditas Therapeutics
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on treating kidney diseases. This chart shows how the company is funding the commercialization of its first approved drug. Debt financing can be used to build a sales and marketing team to bring the innovative drug to the global market.
Market segment debts - Pharma kidney
Calliditas Therapeutics is a biopharmaceutical company focused on treating rare kidney diseases. The path from clinical trials to commercialization of a drug requires significant and risky investment. This chart helps understand the level of financial risk the company considers acceptable to bring its product to market.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Calliditas Therapeutics
Calliditas Therapeutics is a Swedish biopharmaceutical company specializing in kidney diseases. This chart shows its financial structure. For a company with an approved and marketed drug, moderate debt can be a tool for funding marketing. However, increasing debt requires attention to sales growth.
Market segment debt to market segment book capitalization - Pharma kidney
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on treating kidney diseases. This chart shows the debt burden in the biotech sector. It is an indicator of the company's ability to finance its expensive clinical trials and the commercialization of orphan disease drugs.
Debt to book value of all companies in the market
Calliditas Therapeutics is a biopharmaceutical company focused on kidney diseases. Launching and commercializing specialized drugs requires significant investment. This chart of total market debt helps understand the company's funding environment for its key products and how its strategy compares to the pharmaceutical sector.
P/E of the company, segment and market as a whole
P/E - Calliditas Therapeutics
Calliditas Therapeutics is a Swedish pharmaceutical company focused on developing treatments for rare kidney diseases. This chart reflects investor expectations for its lead drug, Tarpeyo. The dynamics depend on sales volumes, progress in obtaining approvals in other countries, and the results of further clinical trials.
P/E of the market segment - Pharma kidney
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on developing treatments for rare kidney diseases with unmet medical needs. Their flagship drug targets IgA nephropathy. This chart shows the average valuation for the pharmaceutical sector, reflecting how investors value companies operating in niche and complex fields.
P/E of the market as a whole
Calliditas Therapeutics is a Swedish biopharmaceutical company specializing in the treatment of kidney diseases. Its valuation depends on the commercial success of its lead drug and the development of new programs. General market sentiment, reflected in this chart, has little impact on its business, which is determined by the specifics of its niche market and the results of clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Calliditas Therapeutics
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on treating rare kidney diseases. Its lead drug is designed for the treatment of IgA nephropathy. This graph reflects expected future revenue from this drug. These projections are dependent on its commercial success in the US and Europe and the expansion of its indications.
%20P%2FE%20Calliditas%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Calliditas-Therapeutics&v=1772625221951 "Chart of the company's future (projected) P/E Calliditas Therapeutics")
Future (projected) P/E of the market segment - Pharma kidney
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on kidney disease treatment, with a leading drug for IgA nephropathy. The chart reflects average profitability expectations for the pharmaceutical sector. CALT's position relative to this benchmark reflects the market's assessment of the commercial potential of their highly specialized drug and the future development pipeline.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-kidney&v=1772625221952 "Future (projected) P/E graph of the market segment - Pharma kidney")
Future (projected) P/E of the market as a whole
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on developing and commercializing drugs for the treatment of rare kidney diseases, particularly IgA nephropathy. This chart of general market expectations provides a backdrop for evaluating highly specialized biotech companies whose success depends on regulatory approval and market acceptance of their innovative drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772625221953 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Calliditas Therapeutics
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on treating kidney diseases. Its financial performance, as shown in the chart, depends on the successful commercialization of its drug, TARPEYO. Sales growth and approvals in new regions are key drivers on the path to stable profitability.
Profit of companies in the market segment - Pharma kidney
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on treating rare kidney diseases, specifically IgA nephropathy. Its success hinges on the commercialization of its drug, Tarpeyo. This chart shows the overall profitability of its segment, illustrating how successfully the industry as a whole is bringing orphan disease therapies to market and monetizing them.
Overall market profit
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on treating kidney diseases. Its success depends on clinical trial results and regulatory approvals, not short-term economic cycles. However, the positive trend in overall market profitability, visible in the chart, improves the investment climate for the entire biotech sector.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Calliditas Therapeutics
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on the treatment of kidney diseases. Its lead product is designed for the treatment of IgA nephropathy. This chart reflects analyst expectations for the commercial success of this drug in the European and US markets, which is a key driver of the company's future profitability.
%20profit%20of%20the%20company%20Calliditas%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Calliditas-Therapeutics&v=1772625221974 "Graph of future (projected) profit of the company Calliditas Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma kidney
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on developing drugs for rare kidney diseases. Its future depends on the success of clinical trials and regulatory approvals. The chart below shows profitability projections for the entire pharmaceutical sector, providing context for assessing the potential of Calliditas' niche strategy.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-kidney&v=1772625221982 "Graph of future (predicted) profits of companies in a market segment - Pharma kidney")
Future (predicted) profit of the market as a whole
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on treating kidney diseases. Its success depends on clinical trial results and regulatory approvals, not short-term economic cycles. This earnings curve does not directly impact its operating performance.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772625221983 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Calliditas Therapeutics
Calliditas Therapeutics is focused on treating a rare kidney disease. This chart shows how the market perceives the commercial potential of its key drug. The dynamics are closely linked to sales growth and reflect investors' confidence in the company's ability to successfully carve out a niche and become a standard of care in this therapeutic area.
P/S market segment - Pharma kidney
Calliditas Therapeutics is a pharmaceutical company focused on treating rare kidney diseases. Its revenue is generated from sales of specialized drugs. This chart shows the average revenue estimate in the pharmaceutical industry. It allows one to estimate the premium the market is willing to pay for Calliditas' unique drug and its potential in a niche market.
P/S of the market as a whole
Calliditas Therapeutics is a Swedish pharmaceutical company focused on developing and commercializing drugs for the treatment of rare kidney diseases. Its lead product is designed for the treatment of IgA nephropathy. This market revenue valuation chart helps understand the premium investors are willing to pay for a drug that addresses an unmet medical need.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Calliditas Therapeutics
Calliditas Therapeutics is a Swedish pharmaceutical company focused on developing and commercializing drugs for rare kidney diseases. This chart shows how the market views the future sales of its lead drug. It reflects investor expectations for its successful clinical implementation and expansion into new markets.
%20P%2FS%20Calliditas%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Calliditas-Therapeutics&v=1772625221995 "The graph of the company's future (projected) P/S Calliditas Therapeutics")
Future (projected) P/S of the market segment - Pharma kidney
Calliditas Therapeutics is a biopharmaceutical company focused on treating rare kidney diseases. Its flagship drug targets a specific type of nephropathy. This chart compares investor expectations for its future revenue with the sector. The high valuation reflects expectations for the commercial success of its niche drug and the potential for expanded indications.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-kidney&v=1772625221997 "Future (projected) P/S market segment graph - Pharma kidney")
Future (projected) P/S of the market as a whole
Calliditas Therapeutics is a biopharmaceutical company focused on treating kidney diseases. Its success depends on scientific developments and regulatory approvals. In the overall revenue growth picture illustrated by the chart, Calliditas represents an innovative sector with a targeted approach to medicine.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772625221998 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Calliditas Therapeutics
Calliditas Therapeutics is a biopharmaceutical company whose revenue is generated by sales of TARPEYO. It is the first approved drug for the treatment of IgA nephropathy, a rare kidney disease. The dynamics in this chart reflect the success of the commercial launch and the level of acceptance by doctors and patients.
Sales of companies in the market segment - Pharma kidney
Calliditas Therapeutics (CALT) specializes in the treatment of the rare kidney disease IgA nephropathy with its drug TARPEYO. This figure reflects the overall revenue of the nephrology pharmaceutical sector. Calliditas' success demonstrates how an innovative approach to orphan diseases allows the company to build and capture a key share in a highly specialized market.
Overall market sales
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on treating rare kidney diseases. While demand for its drugs is driven by medical needs, the economic context is important. This overall activity schedule impacts healthcare system budgets worldwide, which determine the ability to purchase and reimburse innovative drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Calliditas Therapeutics
Calliditas Therapeutics is a Swedish biopharmaceutical company specializing in the treatment of kidney diseases. Its flagship product is designed to treat IgA nephropathy. This chart reflects analyst sales forecasts, which assess the drug's commercial success and its potential to achieve a leading position in the rare kidney disease market.
%20sales%20of%20the%20company%20Calliditas%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Calliditas-Therapeutics&v=1772625222017 "Schedule of future (projected) sales of the company Calliditas Therapeutics")
Future (projected) sales of companies in the market segment - Pharma kidney
Calliditas Therapeutics is a biopharmaceutical company specializing in the treatment of kidney diseases. This forecast chart details expected sales of their flagship drug, likely broken down by geographic market (US, Europe). This shows how analysts assess the global adoption and commercial potential of this specialized therapy.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-kidney&v=1772625222021 "Schedule of future (projected) sales of companies in the market segment - Pharma kidney")
Future (projected) sales of the market as a whole
Calliditas Therapeutics is a Swedish company focused on treating rare kidney diseases. Its success depends on scientific breakthroughs and regulatory approvals. The overall economic climate, reflected in this chart, affects the availability of capital for biotech companies, but Calliditas's key driver remains its research progress.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772625222032 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Calliditas Therapeutics
Calliditas Therapeutics is a biopharmaceutical company focused on treating a rare kidney disease with its drug, Tarpeyo. Its profitability depends almost entirely on the successful commercialization of this single product. The chart shows how the company is translating its scientific advances in a niche medical field into tangible financial returns.
Market segment marginality - Pharma kidney
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on the treatment of kidney diseases. Its lead product, Tarpeyo, is designed to treat primary IgA nephropathy. This chart shows the company's commercial profitability. Success depends on the successful launch of the drug and its acceptance by the medical community.
Market marginality as a whole
Calliditas Therapeutics is a Swedish company specializing in kidney disease treatments. Its success in the US market depends on the reimbursement system. This overall profitability chart reflects the financial health of insurance companies and government programs. Their stability ensures the ability to cover expensive, innovative treatments.
Employees in the company, segment and market as a whole
Number of employees in the company Calliditas Therapeutics
Calliditas Therapeutics is a biopharmaceutical company focused on treating a rare kidney disease. Its core asset is scientific development. This chart illustrates how the company is expanding its scientific and clinical teams as its lead drug advances through key stages of testing and enters the commercial market.
Share of the company's employees Calliditas Therapeutics within the market segment - Pharma kidney
Calliditas Therapeutics is a biopharmaceutical company focused on treating kidney diseases. During the market launch phase of a new drug, the company's staff must include not only scientists but also a strong commercial team. This graph reflects its investment in human capital to promote and sell its specialized medicines.
Number of employees in the market segment - Pharma kidney
Calliditas Therapeutics is focused on treating rare kidney diseases. This chart, illustrating employment in nephrology pharmacology, demonstrates the intensity of research in this niche area. For Calliditas, growing the number of specialists means expanding the scientific community and increasing awareness of the disease their drug targets.
Number of employees in the market as a whole
Calliditas Therapeutics develops innovative treatments for rare kidney diseases. Although demand for medications is inelastic, the overall economic situation, reflected in this graph through employment, impacts the healthcare system. Stable economic growth provides funding for medical programs and insurance, making Calliditas's cutting-edge medications more accessible to patients.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Calliditas Therapeutics (CALT)
Calliditas (CALT) is a biopharmaceutical company focused on treating kidney diseases. In biotech, this metric reveals the essence of the business: enormous market value is often created by a small but highly skilled team of scientists. The chart reflects market expectations for their intellectual property (patents) and the potential of their drugs in the R&D pipeline, not their current headcount.
%20of%20the%20company%20Calliditas%20Therapeutics%20(CALT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Calliditas-Therapeutics-CALT&v=1772625222073 "Chart of market capitalization per employee (in thousands of dollars) of the company Calliditas Therapeutics (CALT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma kidney
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on treating kidney diseases. In biotech, market capitalization reflects the potential of scientific developments. This metric demonstrates the enormous future value the market places on the work of every scientist who can create a breakthrough and in-demand drug.
%20by%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-kidney&v=1772625222076 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma kidney")
Market capitalization per employee (in thousands of dollars) for the overall market
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on treating kidney diseases. Its main asset is the approved drug Tarpeyo. This chart for Calliditas vividly illustrates the model of successful biotech: having a commercialized, patent-protected product creates colossal market value with the help of a relatively small team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772625222080 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Calliditas Therapeutics (CALT)
Calliditas Therapeutics is a biotech company with an approved drug for a rare kidney disease. It's a perfect example of an intellectual property-based business. This chart shows how a small team of scientists and marketers can generate colossal profits from a single patented, high-margin drug.
%20Chart%20Calliditas%20Therapeutics%20(CALT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Calliditas-Therapeutics-CALT&v=1772625222081 "Company Profit Per Employee (in thousands of dollars) Chart Calliditas Therapeutics (CALT)")
Profit per employee (in thousands of dollars) in the market segment - Pharma kidney
Calliditas Therapeutics develops drugs to treat rare kidney diseases. In the highly specialized pharmaceutical industry, success depends on a small but highly skilled team of scientists and clinicians. This metric demonstrates the value each employee brings, which is critical for biotech companies in the R&D phase.
%20in%20the%20market%20segment%20-%20Pharma%20kidney&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-kidney&v=1772625222082 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma kidney")
Profit per employee (in thousands of dollars) for the market as a whole
Calliditas Therapeutics is a Swedish biopharmaceutical company focused on treating rare kidney diseases (such as IgA nephropathy). It's pure R&D. This chart, showing the market average profit per employee, provides important context. It shows how high the stakes are in biotech, where a single successful development can generate colossal profits per scientist.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772625222083 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Calliditas Therapeutics (CALT)
Calliditas Therapeutics is a biopharmaceutical company focused on treating kidney diseases. Its revenue per employee is generated by sales of its first approved drug. The graph shows how successfully the company's commercial team is bringing this specialized product to market and achieving acceptance by the medical community.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Calliditas-Therapeutics-CALT&v=1772625222084 "Sales chart per company employee Calliditas Therapeutics (CALT)")
Sales per employee in the market segment - Pharma kidney
Calliditas Therapeutics (CALT) is a Swedish biopharmaceutical company focused on treating kidney diseases, specifically IgA nephropathy (Tarpeyo). This chart shows the average salary per employee in the pharmaceutical segment. It allows us to assess how effectively Calliditas utilizes its team (sales, R&D) to commercialize its niche drug compared to other biotech companies.
Sales per employee for the market as a whole
Calliditas Therapeutics (CALT) is a biopharmaceutical company focused on kidney disease, with the already approved drug Tarpeyo. This metric is crucial. It demonstrates the transition from R&D expenditures to commercial success. It also demonstrates how effectively their dedicated sales team is monetizing this breakthrough, niche drug.
Short shares by company, segment and market as a whole
Shares shorted by company Calliditas Therapeutics (CALT)
Calliditas (CALT) is a Swedish biopharmaceutical company whose success hinges on the commercialization of its drug Tarpeyo/Nefecon for the treatment of a rare kidney disease (IgA nephropathy). This chart measures short interest. A rise in this indicator could reflect concerns about the drug's speed to market, high competition in this niche, or the company's reliance on a single product. (349)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Calliditas-Therapeutics-CALT&v=1772625222144 "Short Shares Chart for the Company Calliditas Therapeutics (CALT)")
Shares shorted by market segment - Pharma kidney
Calliditas (CALT) is a biopharmaceutical company focused on treating rare kidney diseases. Its success depends not only on its developments but also on the overall biotech climate. The chart below shows the aggregate short position for the sector. It shows how many investors are skeptical of the industry, perhaps anticipating tighter regulations.
Shares shorted by the overall market
Calliditas is a biotech focused on kidney diseases, with an approved drug. This chart illustrates the overall market pessimism. Even with a product, panicked investors may have doubts. They fear that during a crisis, commercialization (market launch) of an expensive drug will be slow, failing to meet expectations.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Calliditas Therapeutics (CALT)
Calliditas Therapeutics (CALT) is a Swedish company whose lead drug (Tarpeyo) is approved for the treatment of a rare kidney disease (IgA nephropathy). It's a niche but important market. This oscillator measures momentum. It shows when the stock is "overheated" (above 70) on sales reports or "oversold" (below 30) due to competitive concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Calliditas-Therapeutics-CALT&v=1772625222151 "RSI 14 indicator chart for the company's stock Calliditas Therapeutics (CALT)")
RSI 14 Market Segment - Pharma kidney
Calliditas Therapeutics is a Swedish biopharmaceutical company specializing in the development of drugs for the treatment of rare kidney diseases, specifically IgA nephropathy (Tarpeyo). This chart measures the overall momentum in the pharmaceutical sector. It helps differentiate CALT's movement from the overall industry trend.
RSI 14 for the overall market
For Calliditas Therapeutics, a biotech in R&D, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast CALT (Calliditas Therapeutics)
Calliditas Therapeutics is a Swedish biopharmaceutical company whose key product, Tarpeyo, is approved for the treatment of a rare kidney disease (IgA nephropathy). This chart shows the analysts' average 12-month forecast, reflecting their assessment of the commercial success and adoption rate of this niche drug.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-CALT-Calliditas-Therapeutics&v=1772625222161 "A chart showing analyst consensus forecasts for the expected stock price. CALT (Calliditas Therapeutics)")
The difference between the consensus estimate and the actual stock price CALT (Calliditas Therapeutics)
Calliditas (CALT) is a Swedish biopharmaceutical company whose success is built on Tarpeyo/Nefecon, the first approved drug for the rare kidney disease IgA nephropathy. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in the commercial launch of this niche drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-CALT-Calliditas-Therapeutics&v=1772625222163 "A chart showing the difference between the consensus forecast and the actual stock price. CALT (Calliditas Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma kidney
Calliditas (CALT) is a Swedish biotech company that developed Tarpeyo, the first approved drug for the rare kidney disease IgA nephropathy. This chart shows analysts' overall expectations for the kidney pharmaceutical sector, reflecting their belief in the commercial success of this niche drug.
Analysts' consensus forecast for the overall market share price
Calliditas (CALT) is a Swedish biopharmaceutical company. Their breakthrough is an approved drug (Tarpeyo) for the treatment of a rare kidney disease (IgA nephropathy), which previously had no specific treatment. This chart shows the overall risk appetite, reflecting investors' confidence in the commercial success and the willingness of insurers to cover new, expensive drugs.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Calliditas Therapeutics
Calliditas is a biotech company that has crossed the finish line. Their single FDA-approved drug (Tarpeyo) is the first targeted therapy for a rare kidney disease (IgAN). This chart summarizes their commercialization history, reflecting their (slow but growing) sales growth for this ultra-niche, expensive drug.
AKIMA Market Segment Index - Pharma kidney
Calliditas Therapeutics is a Swedish pharmaceutical company focused on kidney diseases. Their drug Nefecon was the first approved treatment for the rare disease IgA nephropathy. This chart compares their composite index to the sector, showing how their kidney specialization compares to others.
The AKIM Index for the overall market
Calliditas Therapeutics is a Swedish biopharmaceutical company specializing in rare kidney diseases (Tarpeyo for IgA nephropathy). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this commercial success story from Europe compares to overall economic trends.
